152 related articles for article (PubMed ID: 24845463)
21. Dipeptidyl-peptidase IV inhibitor-associated bullous pemphigoid efficiently treated with omalizumab.
Garrido PM; Alexandre MI; Travassos AR; Filipe P
Dermatol Ther; 2020 Nov; 33(6):e14160. PubMed ID: 32770711
[No Abstract] [Full Text] [Related]
22. Targeted Therapies for Autoimmune Bullous Diseases: Current Status.
Amber KT; Maglie R; Solimani F; Eming R; Hertl M
Drugs; 2018 Oct; 78(15):1527-1548. PubMed ID: 30238396
[TBL] [Abstract][Full Text] [Related]
23. Calcitriol exerts anti-inflammatory effects in keratinocytes treated with autoantibodies from a patient with bullous pemphigoid.
Tukaj S; Grüner D; Tukaj C; Zillikens D; Kasperkiewicz M
J Eur Acad Dermatol Venereol; 2016 Feb; 30(2):288-92. PubMed ID: 25610950
[TBL] [Abstract][Full Text] [Related]
24. Commentary: Omalizumab therapy for bullous pemphigoid by KK Yu, AB Crew, KAN Messingham, JA Fairley, DT Woodley. J Am Acad Dermatol 2014 Jun 20. pii: S0190-9622(14)01410-8. doi: 10.1016/j.jaad.2014.04.053. [Epub ahead of print].
Yancey KB
Dermatol Ther; 2015; 28(1):3. PubMed ID: 25286315
[No Abstract] [Full Text] [Related]
25. Effects of Omalizumab on FcεRI and IgE Expression in Lesional Skin of Bullous Pemphigoid.
Seyed Jafari SM; Gadaldi K; Feldmeyer L; Yawalkar N; Borradori L; Schlapbach C
Front Immunol; 2019; 10():1919. PubMed ID: 31474990
[TBL] [Abstract][Full Text] [Related]
26. IgE-mediated mechanisms in bullous pemphigoid and other autoimmune bullous diseases.
van Beek N; Schulze FS; Zillikens D; Schmidt E
Expert Rev Clin Immunol; 2016; 12(3):267-77. PubMed ID: 26588556
[TBL] [Abstract][Full Text] [Related]
27. Immunoglobulin E and bullous pemphigoid.
Cozzani E; Gasparini G; Di Zenzo G; Parodi A
Eur J Dermatol; 2018 Aug; 28(4):440-448. PubMed ID: 30325326
[TBL] [Abstract][Full Text] [Related]
28. Research progress of omalizumab in the treatment of bullous pemphigoid.
Ling X; Shou X; Lou Y; Ling J; Zhang M; Yu T; Gu W
J Dermatol; 2023 May; 50(5):575-587. PubMed ID: 36971190
[TBL] [Abstract][Full Text] [Related]
29. The cytokine milieu of bullous pemphigoid: Current and novel therapeutic targets.
Maglie R; Solimani F; Didona D; Pipitò C; Antiga E; Di Zenzo G
Front Med (Lausanne); 2023; 10():1128154. PubMed ID: 36814775
[TBL] [Abstract][Full Text] [Related]
30. What's new in the pathogeneses and triggering factors of bullous pemphigoid.
Ujiie H
J Dermatol; 2023 Feb; 50(2):140-149. PubMed ID: 36412277
[TBL] [Abstract][Full Text] [Related]
31. Updated S2 K guidelines for the management of bullous pemphigoid initiated by the European Academy of Dermatology and Venereology (EADV).
Borradori L; Van Beek N; Feliciani C; Tedbirt B; Antiga E; Bergman R; Böckle BC; Caproni M; Caux F; Chandran NS; Cianchini G; Daneshpazhooh M; De D; Didona D; Di Zenzo GM; Dmochowski M; Drenovska K; Ehrchen J; Goebeler M; Groves R; Günther C; Horvath B; Hertl M; Hofmann S; Ioannides D; Itzlinger-Monshi B; Jedličková J; Kowalewski C; Kridin K; Lim YL; Marinovic B; Marzano AV; Mascaro JM; Meijer JM; Murrell D; Patsatsi K; Pincelli C; Prost C; Rappersberger K; Sárdy M; Setterfield J; Shahid M; Sprecher E; Tasanen K; Uzun S; Vassileva S; Vestergaard K; Vorobyev A; Vujic I; Wang G; Wozniak K; Yayli S; Zambruno G; Zillikens D; Schmidt E; Joly P
J Eur Acad Dermatol Venereol; 2022 Oct; 36(10):1689-1704. PubMed ID: 35766904
[TBL] [Abstract][Full Text] [Related]
32. Immunoglobulin E-Mediated Autoimmunity.
Maurer M; Altrichter S; Schmetzer O; Scheffel J; Church MK; Metz M
Front Immunol; 2018; 9():689. PubMed ID: 29686678
[TBL] [Abstract][Full Text] [Related]
33. BPDAI and ABSIS correlate with serum anti-BP180 NC16A IgG but not with anti-BP230 IgG in patients with bullous pemphigoid.
Daneshpazhooh M; Ghiasi M; Lajevardi V; Nasiri N; Balighi K; Teimourpour A; Khosravi H; Saeidi V; Mahmoudi H; Chams-Davatchi C
Arch Dermatol Res; 2018 Apr; 310(3):255-259. PubMed ID: 29423547
[TBL] [Abstract][Full Text] [Related]
34. Biological treatment for bullous pemphigoid.
Oren-Shabtai M; Mimouni D; Nosrati A; Atzmony L; Kaplan B; Barzilai A; Baum S
Front Immunol; 2023; 14():1157250. PubMed ID: 37180101
[TBL] [Abstract][Full Text] [Related]
35. Omalizumab as a corticosteroid-sparing agent in the treatment of bullous pemphigoid.
Vassallo C; Somenzi A; De Amici M; Barruscotti S; Brazzelli V
Dermatol Ther; 2022 Dec; 35(12):e15946. PubMed ID: 36259470
[TBL] [Abstract][Full Text] [Related]
36. Correlation between serum immunoglobulin levels and retinal structure in patients with newly diagnosed Vogt‑Koyanagi‑Harada disease.
Jiang Z; Zhang N; Ji H; Zhu M; Zhou M; Dong J
Mol Med Rep; 2022 Sep; 26(3):. PubMed ID: 35904174
[TBL] [Abstract][Full Text] [Related]
37. Insights Into the Pathogenesis of Bullous Pemphigoid: The Role of Complement-Independent Mechanisms.
Cole C; Vinay K; Borradori L; Amber KT
Front Immunol; 2022; 13():912876. PubMed ID: 35874745
[TBL] [Abstract][Full Text] [Related]
38. Rituximab, Omalizumab, and Dupilumab Treatment Outcomes in Bullous Pemphigoid: A Systematic Review.
Cao P; Xu W; Zhang L
Front Immunol; 2022; 13():928621. PubMed ID: 35769474
[TBL] [Abstract][Full Text] [Related]
39. Case Report: Combination of Omalizumab and Dupilumab for Recalcitrant Bullous Pemphigoid.
Seyed Jafari SM; Feldmeyer L; Bossart S; Simon D; Schlapbach C; Borradori L
Front Immunol; 2020; 11():611549. PubMed ID: 33584689
[TBL] [Abstract][Full Text] [Related]
40. Increasing evidence for omalizumab in the treatment of bullous pemphigoid.
Lonowski S; Sachsman S; Patel N; Truong A; Holland V
JAAD Case Rep; 2020 Mar; 6(3):228-233. PubMed ID: 32140524
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
